This trial is active, not recruiting.

Condition lymphoma
Treatments rna analysis, gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis
Sponsor Southwest Oncology Group
Collaborator National Cancer Institute (NCI)
Start date February 2012
End date March 2012
Trial size 220 participants
Trial identifier NCT01563861, CDR0000729157, S9704-S0014-S0313A, U10CA032102


RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors find better ways to treat cancer.

PURPOSE: This research trial studies genes in samples from patients with limited and advanced diffuse large B-cell lymphoma.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Time perspective retrospective

Primary Outcomes

Proportion of GCB phenotype among limited-stage vs advanced-stage patients
time frame: Retrospectively
Differences in PFS between limited- and advanced-stage patients with the GCB and non-GCB phenotypes
time frame: Retrospectively
Association between GCB markers and OS
time frame: Retrospectively

Eligibility Criteria

Male or female participants at least 18 years old.

DISEASE CHARACTERISTICS: - Diffuse large B-cell lymphoma - Initial diagnostic tissue block, or 4 unstained slides - Tissue from patients with limited-stage DLBCL enrolled on SWOG trials treated with cyclophosphamide, doxorubicin hydrochloride, prednisone, and vincristine sulfate (CHOP), and monoclonal anti-CD20 antibody backbone - SWOG-S0014 - SWOG-S0313 - Tissue from patients with advanced-stage DLBCL enrolled on SWOG trials treated with CHOP and monoclonal anti-CD20 antibody backbone - SWOG-S9704 - SWOG-S0433 - SWOG-S0515 - SWOG-S0806 PATIENT CHARACTERISTICS: - Not specified PRIOR CONCURRENT THERAPY: - See Disease Characteristics

Additional Information

Official title Determining the Cell of Origin and Prognostic Gene Signatures in SWOG Trials of Diffuse Large B-Cell Lymphoma
Principal investigator Daniel O. Persky, MD
Description OBJECTIVES: - To determine the proportion of the cell of origin subtypes (germinal center B-cell-like [GCB] vs non-GCB) and expression levels of prognostic genes previously identified in diffuse large B-cell lymphoma (DLBCL) in patient biopsy samples from SWOG trials of limited- and advanced-stage DLBCL, and to assess the association between the results and progression-free survival (PFS). - To assess the association between these marker results and overall survival (OS). OUTLINE: Archived formalin-fixed paraffin-embedded tissue are analyzed for gene expression profile by quantitative nuclease protection assay (qNPA) and immunohistochemical analyses. Results are then compared with each patient's progression-free survival and overall survival.
Trial information was received from ClinicalTrials.gov and was last updated in September 2015.
Information provided to ClinicalTrials.gov by Southwest Oncology Group.
Location data was received from the National Cancer Institute and was last updated in June 2016.